SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Red Crescent: More than 100,000 civilian structures damaged in Iran - 2NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- 3Where America’s CO2 emissions come from – what you need to know, in charts
- 4These 45 exoplanets may be the best places to search for alien life
- 5UN warns civil liberties under threat due to war in Middle East
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- AfD faction in western Germany ousts councilman for firebrand speech
- Vote In favor of Your Number one Game Control center
- Vote in favor of your Favored kind of pasta
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- Bestselling author Colleen Hoover reveals cancer journey
- After toilet and email issues, Artemis II astronauts fire engine to head for the moon
- Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
